SCS Capital Management’s AstraZeneca AZN Stock Holding History

SCS Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.8M	Sell	84,223 -3,126	-4%	-$588K	0.15%	90
2026 Q1	$17M	Buy	87,349 +71,321	+445%	+$13.8M	0.18%	71
2025 Q4	$2.95M	Sell	16,028 -75,776	-83%	-$13.3M	0.03%	182
2025 Q3	$14.1M	Sell	91,804 -220	-0.2%	-$33.3K	0.15%	90
2025 Q2	$12.9M	Buy	92,024 +71,165	+341%	+$9.97M	0.14%	94
2025 Q1	$3.07M	Buy	+20,859	New	+$3.02M	0.04%	157

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SCS Capital Management's AZN Position: Q2 2026 in Review

SCS Capital Management reduced its AstraZeneca (AZN) stake by 3.6% in Q2 2026, selling an estimated $588K and leaving 84,223 shares worth $15.8M. The position accounts for 0.15% of the portfolio, ranked #90.

SCS Capital Management first reported a position in AZN in Q1 2025 and has held it in 6 quarters since. The position peaked at $17M in Q1 2026. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

SCS Capital Management held 84,223 shares of AstraZeneca worth $15.8M as of Q2 2026.
SCS Capital Management sold 3,126 AstraZeneca shares in Q2 2026, an estimated $588K.
AstraZeneca made up 0.15% of SCS Capital Management's portfolio in Q2 2026, its #90 holding.
SCS Capital Management first reported a position in AstraZeneca in Q1 2025 and has held it in 6 quarters since.
SCS Capital Management's AstraZeneca position peaked at $17M in Q1 2026.
1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.